Cargando…

Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians

BACKGROUND: In women with early breast cancer, a pathological complete response (pCR) after neoadjuvant chemotherapy is reported to be associated with an improvement of the survival. The aim of this survey among physicians was to investigate whether the probability of achieving pCR in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gass, Paul, Untch, Michael, Müller, Volkmar, Möbus, Volker, Thomssen, Christoph, Häberle, Lothar, Erber, Ramona, Hein, Alexander, Jud, Sebastian Michael, Lux, Michael P., Hack, Carolin C., Hartmann, Arndt, Kolberg, Hans-Christian, Ettl, Johannes, Lüftner, Diana, Jackisch, Christian, Beckmann, Matthias W., Janni, Wolfgang, Schneeweiss, Andreas, Fasching, Peter A., Nabieva, Naiba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Georg Thieme Verlag KG 2018
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6059863/ https://www.ncbi.nlm.nih.gov/pubmed/30057427 http://dx.doi.org/10.1055/a-0642-9462

Ejemplares similares

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

Update Breast Cancer 2019 Part 1 – Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice
por: Janni, Wolfgang, et al.
Publicado: (2019)

Risk, Prediction and Prevention of Hereditary Breast Cancer – Large-Scale Genomic Studies in Times of Big and Smart Data
por: Wunderle, Marius, et al.
Publicado: (2018)

Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer — Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Advanced Breast Cancer: AGO Recommendations 2022 – Focus on ABC6 Consensus
por: Untch, Michael, et al.
Publicado: (2022)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Update Breast Cancer 2018 (Part 4) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Treatment Strategies for Advanced Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 3) – Genomics, Individualized Medicine and Immune Therapies – in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer
por: Wöckel, Achim, et al.
Publicado: (2018)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Treatment of Patients with Early Breast Cancer: Evidence, Controversies, Consensus: German Expert Opinions on the 17th International St. Gallen Consensus Conference
por: Untch, Michael, et al.
Publicado: (2021)

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
por: Taran, Florin-Andrei, et al.
Publicado: (2018)

Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Correction: Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine
por: Laakmann, Elena, et al.
Publicado: (2020)

Return of individual genomic research results within the PRAEGNANT multicenter registry study
por: Huebner, Hanna, et al.
Publicado: (2022)

Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany
por: Huebner, Hanna, et al.
Publicado: (2020)

Update Breast Cancer 2020 Part 5 – Moving Therapies From Advanced to Early Breast Cancer Patients
por: Lux, Michael P., et al.
Publicado: (2021)

Update Breast Cancer 2021 Part 1 – Prevention and Early Stages
por: Stickeler, Elmar, et al.
Publicado: (2021)

Update Breast Cancer 2021 Part 2 – Advanced Stages, Long-Term Consequences and Biomarkers
por: Ditsch, Nina, et al.
Publicado: (2021)

HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment
por: Wuerfel, Franziska M., et al.
Publicado: (2020)

Analysis of motives and patient satisfaction in oncological second opinions provided by a certified university breast and gynecological cancer center
por: Loehberg, Christian R., et al.
Publicado: (2020)

Mammographic density and prognosis in primary breast cancer patients
por: Heindl, Felix, et al.
Publicado: (2021)

Update Breast Cancer 2021 Part 4 – Prevention and Early Stages
por: Thomssen, Christoph, et al.
Publicado: (2022)

Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

Correction: Update Breast Cancer 2021 Part 5 – Advanced Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2022)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
por: Engler, Tobias, et al.
Publicado: (2022)

Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients
por: Erber, Ramona, et al.
Publicado: (2020)

4th International Consensus Conference on Advanced Breast Cancer (ABC4), Lisbon, November 4, 2017 : ABC4 Consensus: Assessment by a Panel of German Experts
por: Untch, Michael, et al.
Publicado: (2018)

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
por: Aktas, Bahriye, et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2022)

Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
por: Nabieva, Naiba, et al.
Publicado: (2021)

CDK4/6 Inhibitors—Overcoming Endocrine Resistance Is the Standard in Patients with Hormone Receptor-Positive Breast Cancer
por: Nabieva, Naiba, et al.
Publicado: (2023)

Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer
por: Gass, Paul, et al.
Publicado: (2018)

Can contemporary trials of chemotherapy for HER2-negative metastatic breast cancer detect overall survival benefit?
por: Kümmel, Sherko, et al.
Publicado: (2018)

Update Breast Cancer 2020 Part 4 – Advanced Breast Cancer
por: Tesch, Hans, et al.
Publicado: (2020)

Update Breast Cancer 2020 Part 2 – Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics
por: Lüftner, Diana, et al.
Publicado: (2020)

Update Breast Cancer 2020 Part 1 – Early Breast Cancer: Consolidation of Knowledge About Known Therapies
por: Schneeweiss, Andreas, et al.
Publicado: (2020)

Update Breast Cancer 2023 Part 3 – Expert Opinions of Early Stage Breast Cancer Therapies
por: Kolberg, Hans-Christian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_pfngv5srgql4nee515i35imlkl